Read more
We are pleased to present our readers the Proceedings of the International Symposium "New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasma pheresis" which was held in Freiburg i. Br. (FRG) during Oct tober 6-8, 1988. The meeting was held on the occasion of opening the new dialysis unit of the University Hospital of Freiburg i. Br .. The topics discussed included membrane biocompatibility, catabolic factors associated with dialysis therapy, phar macological therapy in dialyzed patients, erythropoietin and renal anemia, new developments in CAVH, CAPD and plasmapheresis, renal replacement therapy in acute renal failure, and plasmapheresis therapy in systemic diseases. It was unfortunately impossible in this volume, to include the extended, lively and stimulating discussions which were enjoyed by the participants during the conference. The meeting has provided an unique framework for close interaction between scientists from various disciplines, including nephrology, pharmacology, hematology, cardiology, anesthesiology, surgery, intensive care medicine, and patho logy. We would like to express our gratitude and appreciation for all those who have stimulated, encouraged and supported us to hold the symposium in Freiburg. This endeaver could not have been possible without the generous financial support of Asid-Bonz (BOblingen), Bayer AG (Leverkusen), Bayropharm GmbH (Koln), Baxter (Munchen), Ciba-Geigy (Wehr/Baden), Cilag GmbH (Sulzbach), Fresenius AG (Oberursel), Gambro (Martinsried), Gry~Pharma GmbH (Kirchzarten), Hoechst AG (Frankfurt), Hospal (Nurnberg), Knoll AG (Ludwigshafen), Lederle-Cyanamid (Wolfratshausen), E. Merck (Darmstadt), MSD Sharp and Dohme GmbH (Munchen), Pfizer GmbH (Karlsruhe), and pfrimmer and Co (Erlangen) .
List of contents
I New Perspectives in Hemodialysis.- Protein catabolic factors in patients on renal replacement therapy.- ?2 Microglobulin-derived amyloid in dialysis patients.- Mechanisms and consequences of complement activation during hemodialysis.- Neutrophil activation during hemodialysis.- Biocompatibility - a system approach.- Treatment of uremic anaemia with recombinant human erythropoietin.- Endocrine abnormalities in patients with endstage renal failure.- Carnitine supplementation in uremia.- II Pharmacological Therapy in Dialyzed Patients.- Pathophysiology and treatment of hypertension in dialysis patients.- Adjustment of drug dosage to hemodialysis patients.- Pharmacokinetic aspects of drug transport in continuous ambulatory peritoneal dialysis.- Drug therapy during continuous arteriovenous hemofiltration.- III New Perspectives in Peritoneal Dialysis.- The biology of the peritoneal membrane during chronic peritoneal dialysis.- Lymphatic absorption during peritoneal dialysis.- CAPD with bicarbonate solution.- Glucose polymer as an osmotic agent in CAPD.- Effects of long-term treatment with human recombinant erythropoietin in patients on CAPD.- IV New Perspectives in Hemofiltration and Plasmapheresis.- Continuous arterio-venous hemofiltration: Optimization of technical procedures and new directions.- Is continuous haemofiltration superior to intermittent dialysis and haemofiltration treatment?.- Therapeutic apheresis update.- Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus.
